By Fineline Cube 
Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY), this week entered into a second multi-year collaboration agreement with US-based Orionis Biosciences Inc. The partnership aims to discover small-molecule monovalent glue medicines in oncology, following their initial collaboration in September 2023 focused on discovering novel small-molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration.
Collaboration Details
Under the deal, Orionis will be responsible for the discovery and optimization of molecular glues, while Genentech will handle subsequent later-stage preclinical and clinical development, regulatory filing, and commercialization of these small molecules. This division of responsibilities leverages the strengths of both companies to accelerate the development of innovative treatments.
Financial Terms
Orionis will receive an upfront payment of USD 105 million and is eligible for potential research, development, commercial, and net sales milestone payments, totaling more than USD 2 billion. Additionally, Orionis will receive sales-based tiered royalties, further incentivizing the successful development and commercialization of these small-molecule medicines.-Fineline Info & Tech